Mice Model Market Share Report & Trend Analysis 2028

[Research Report] The mice model market is expected to grow from US$ 1,705.70 million in 2022 to US$ 2,340.90 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2022 to 2028.

Analyst Viewpoint:

Mice models play an essential role in the drug discovery process during the pre-clinical trials process. For example, mice models targeted for pre-clinical trials demonstrate metabolism and absorption with general safety and efficacy for new medicines. Also, a mouse strain with relevant disease symptoms offers a primary, effective, and efficient model that plays an important role in drug discovery. The main purpose of mice models targeted for the pre-clinical drug discovery process is due to mice having similar genomic levels and disease pathophysiology in mice similar to humans. Therefore, such a combination of features offers researchers a uniquely powerful tool to understand the mechanism of human disease and testing of novel drug therapies. Growing usage of mice models in virology and infectious disease and growing consumption of personalized medicine for studying the humanized mice models are the most impacting factors responsible for the influential growth of the mice models market during the forecast period.

Market Dynamics

Growing Usage of Mice Models in Virology and Infectious Diseases Bolster the Growth of Mice Model Market

Mice models are essential tools for studying the pathogenesis of infectious diseases and for the preclinical evaluation of vaccines and therapies against various human pathogens. The use of genetically defined inbred mouse strains, humanized mice, and gene knockout mice has enabled the research community to study how pathogens cause diseases and explain the role of specific host genes in controlling or promoting diseases. It also helps determine potential targets for prevention or identify treatments for various infectious agents. With the emergence of new infectious diseases, the animal model has become a vital tool for studying disease mechanisms and developing therapeutics.

Mice with xenografted human immune systems have been used to study the pathogenesis of various infectious agents, including Plasmodium falciparum (malaria), Mycobacterium tuberculosis, dengue virus, and influenza virus. These models have been beneficial in studying HIV, which includes analyzing viral and host factors that promote viral replication and HIV interactions with the host's immune response. They are also helpful as platforms for testing therapeutic approaches to control or cure HIV infection.

Mouse models are widely used for preclinical screening of vaccines/therapies because of their reproducibility, low cost, and ease of experimental manipulation. Over the past century, advancements in vaccines, antibiotics/antivirals, and infection control measures have significantly reduced the burden of infectious diseases on public health. However, there has been an increase in contagious viral diseases over the years. In the past two decades, there have been 3 outbreaks of coronavirus─SARS-CoV in 2002, Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) in 2012, and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in 2019. However, the current SARS-CoV-2 is much more severe than the SARS-CoV in 2002 and has spread across more than 213 countries, affecting millions of people. The emergence of the novel coronavirus disease (COVID-19) in 2019 prompted the study of animal models to develop an effective treatment for it.

Aside from coronavirus studies, mouse models are considered the best small animal models to be tested for hepatitis B virus (HBV), hepatitis C virus (HCV), Zika virus, and cytomegalovirus (CMV). According to the WHO, more than 17 million people die from infectious diseases yearly. Over the past 2 decades, over 30 new infectious diseases have emerged. According to UNAIDS, 38 million people were affected by HIV by the end of 2019. Mouse models have been widely used for various viral studies due to their small size, low cost, ease of use, and high reproducibility.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Mice Model Market: Strategic Insights

Market Size Value in	US$ 1,705.70 Million in 2022
Market Size Value by	US$ 2,340.90 Million by 2028
Growth rate	CAGR of 5.4% from 2022 to 2028
Forecast Period	2022-2028
Base Year	2022

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Future Trends

Rising Advancements in Gene Editing Tools

Mice have been used extensively as a small animal model. Many genetically engineered mice models have emerged over the past 2 decades. The advent of gene-specific nucleases has accelerated their generation in recent years. Significant advances have been made in biotechnology in recent years, and the genetic engineering branch is advancing at an unprecedented rate, bringing numerous benefits. Genome editing technology has revolutionized genetic and biological research by providing a novel ability to precisely manipulate and modify the genomes of living organisms and accelerating the study of functional genomics.

Various genome editing tools have recently been used to study simple and complicated genomes. The development of meganuclease-engineered zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and, more recently, the CRISPR-Cas9 system has undoubtedly revolutionized genome editing and opened up new possibilities, particularly in the rat and other species, in which embryonic stem cells (ESC) were not available.

Furthermore, transgenic mice were created by incorporating Cas9 into mouse zygotes to understand the pathophysiology of cardiovascular diseases. The CRISPR-Cas9 system was used to generate Kcnj13 mutant mice to study ocular diseases. The technology also helped researchers create different types of immunodeficient mice models.

Report Segmentation and Scope

The “Global Mice Model Market” is segmented based on type, service, technology, indication, mode, application, end user, and geography. Based on type, the mice model market is segmented into inbred mice, genetically engineered mice, hybrid mice, spontaneous mutant mice, outbred mice, and surgically modified mice. Based on service, the mice model market is segmented into breeding, cryopreservation, genetic testing, model-in licensing, quarantine, and others. By technology, the mice model market is segmented as CRISPR, microinjection, nuclear transfer, embryonic stem cell injection, and others. By indication, the mice model market is segmented as oncology studies, genetic studies, infectious disease studies, endocrine metabolic studies, fibrosis, central nervous system (CNS) studies, immunology and inflammation studies, cardiovascular studies, and other disease studies. By mode, the mice model market is bifurcated into outsourced and in-house. By application, the mice model market is segmented as pre-clinical drug development, biomarker analysis, and basic cancer research. By end user, the mice model market is segmented as academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and others. The mice model market based on geography is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Russia, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America)

Segmental Analysis:

Based on technology, the mice model market is segmented into CRISPR, microinjection, nuclear transfer, embryonic stem cell injection, and others. The CRISPR segment held a larger share of the market in 2022 and knockout the others segment accounting least market share. The expanded form of CRISPR is Clustered Regularly Interspaced Short Palindromic Repeats. CRISPR is a highly precise gene-editing tool that can change the research landscape in mice and humans. CRISPR works in most mouse strains; thus, new mutations can be directly generated in a genetic background of choice. Thus, this technology's optimized and efficient use eliminates the need, time, and resources to backcross mutations from one genetic background to another, which is a typical practice when generating mutant mice by traditional methods.

Moreover, this technology's mice models are used to understand disease manifestation and potential therapies. For instance, a study published in Springer Nature Limited in 2021 entitled "In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice" revealed that gene therapy using "base editor" derived from CRISPR extends the life span in mice with progeria. Hutchinson-Gilford progeria syndrome (progeria) is an extremely rare, progressive genetic disorder that causes children to age rapidly, starting in their first two years. Children with progeria generally appear normal at birth. Thus, the increasing use of this technology in mice models to manipulate or edit the nucleic material is expected to contribute to the growth of this segment.

Mice Model Market, by Type – 2022 and 2030

Access Data

Based on indication, the mice models market is segmented as oncology studies, genetic studies, infectious disease studies, endocrine metabolic studies, fibrosis, central nervous system (CNS) studies, immunology and inflammation studies, cardiovascular studies, and other disease studies. The oncology studies segment is anticipated to hold the largest share of the mice model market in 2022 and is estimated to register the highest CAGR of 6.1% during the forecast period. Mouse cancer models enable researchers to learn about tumor biology in complicated and dynamic physiological systems. Metastasis is a complex process involving a series of steps in which cancer cells leave the original tumor site and move to other body parts through the bloodstream or lymphatic system. Since metastasis is one of the leading causes of cancer death, it is essential to identify the critical genetic events for metastasis. The two mouse models have been beneficial in studying metastatic genetic engineering models and xenograft model systems. Since gene targeting was developed in mice, cancer biologists have been among the most frequent users of transgenic mouse models, dramatically increasing knowledge about how cancers form and grow.

Moreover, using existing mouse models in cancer research is of utmost importance as they aim to explore the link between candidate cancer genes and carcinogenesis and provide models to develop and test new therapies. For instance, a study published in Springer Nature in 2022 entitled "Testicular cancer in mice: interplay between stem cells and endocrine insults" revealed that the Mouse model for T2GCT has immense potential to understand cancer initiation cancer stem cells and also to develop effective therapies in the near future. Therefore, the vast amount of research over the last 30 years led to the development of powerful mouse cancer models. These models are important tools for current and future cancer research, thus fueling this segment's growth.

Regional Analysis:

Based on geography, the mice models market is divided into five key regions: North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. In 2022, North America held the largest share of the mice models market, and Asia Pacific is estimated to register the highest CAGR during the forecast period. Asia Pacific (APAC) is the fastest-growing regional market for mice models. The market in APAC is segmented into China, India, Japan, South Korea, Australia, and the Rest of APAC. Increasing prevalence of infectious and viral diseases and rising product launches are fueling the growth of the market in the region. In addition, several market players are focusing on countries in Asia Pacific for geographical expansion and other strategies. Therefore, the region holds a huge potential for mice model market players.

Industry Developments and Future Opportunities: 

Various initiatives taken by key players operating in the global mice models market are listed below:

1. In April 2022, Taconic and LifeCanvas are collaborating to investigate how the disease develops and progresses, using advanced 3D histology with two Taconic mouse models used to study Alzheimer's disease.
2. In January 2022, Trans Genic Inc. signed a joint research agreement on gene modification experiments using humanized mice. This joint research is a new genome editing technology has exclusively licensed the patent CRISPR-Cas3 2Regarding the usefulness of the system, the company have developed familial amyloid polyneuropathy (systemic amyloidosis). CRISPR-Cas3 This will be a study that will be evaluated using TTR exon humanized mice involved in and will lead to new gene therapies for future hereditary diseases.
3. In January 2022, Charles River Laboratories Inc. Scientists at La Jolla Institute for Immunology (LJI) and Charles River are launched a new collaboration to uncover how different cells in the human immune system respond to early SARS-CoV-2 infection, the virus that causes COVID-19. This new research will allow scientists around the world to better capture human response during early infection.
4. In September 2021, Envigo RMS Holding Corp. collaborated with Biocytogen. The two companies are committed to supporting research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the United States, Europe, and certain Asia-Pacific regions. This mouse model is highly immunodeficient and capable of supporting human immune cell transplantation. The model is widely used in research and drug discovery in many fields including oncology, immuno-oncology, infectious disease, and stem cell biology.
5. In December 2020, genOway and Cyagen, two innovative companies and leaders in the creation of genetically engineered rodent models, announced a partnership to commercialize high-standard preclinical humanized immune checkpoint and immunodeficient BRGSF mouse models to non-profit and for-profit organizations in the Asia-Pacific region from 2020.

Competitive Landscape and Key Companies:

Some of the prominent players operating in the global mice model market include Charles River Laboratories; The Jackson Laboratory; Taconic Biosciences; TRANS GENIC INC.; GenOway S.A.; Envigo; Janvier Labs; Ozgene Pty Ltd.; Crown Bioscience Inc.; and Harbour BioMed among others. These companies focus on new product launches and geographical expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence, which provides them to serve a large set of customers and subsequently increases their market share.